Own Endless Biotech Shares for Just $1!

Watch our exclusive explainer video and discover how Endless Biotech is revolutionizing cultivation to meet the growing global demand.

Why Endless Biotech?

At Endless Biotech, we’re transforming the industry with cutting-edge tissue culture solutions, advanced genetics, and AI-powered automation. With a Nasdaq listing in our sights by 2028, this is your chance to join us at the ground floor of innovation.

  • $1 Per Share: Affordable entry into a biotech poised for massive growth.
  • $11 Million Contracted Sales: Proven success in 2024 and beyond.
  • Future-Focused Vision: Leveraging CRISPR, robotics, and sustainable cultivation methods.

How to Get Started

Secure Your Shares

Be among the first to reserve your stake in our $1 public offering.

Join the Revolution

Align yourself with a biotech leader driving the next wave of innovation.

See How Endless Biotech is Revolutionizing Cultivation and Scaling Globally

Reserve Your Shares
Reserve Your Shares

Virtual Tour

Navigate through our facility at your own pace, explore each step of our process, and gain insight into the technologies that set Endless Biotech apart.

Secure Your Shares

Be among the first to reserve your stake in our $1 public offering.

Early Stage Investment

Reserve Your $1 Shares Today!

Thank you!
Your submission has been received!
Something went wrong while submitting the form.

Forward looking statements: These offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Please note investors in this offering will be clients of the issuer and not Dalmore Group, LLC (“Dalmore”), a registered broker-dealer and member FINRA/SIPC. Dalmore’s role in the transaction is to facilitate back-office and regulatory functions related to the Regulation A transaction, and acts only as the broker/dealer of record for the offering listed. Dalmore is not providing investment advice or recommendations, or legal or tax advice.

This Reg A investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. All investors should make their own determination, with the assistance of their own financial or other advisors, as to whether or not to make any investment, based on their own independent evaluation, analysis, and circumstances.

No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. An offering statement regarding this offering has been filed with the SEC. You may obtain a copy of the preliminary offering circular that is part of that offering statement. [Form 1-A filing with SEC]